Trials / Completed
CompletedNCT01876745
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy of NovoSeven® (activated recombinant factor VII, eptacog alfa (activated)) during bleeding episodes and for the prevention of bleeding during surgery/delivery in patients with Glanzmann's thrombasthenia (GT)/Glanzmann's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) | Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study. |
Timeline
- Start date
- 2014-10-07
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2013-06-13
- Last updated
- 2017-07-11
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01876745. Inclusion in this directory is not an endorsement.